NautaDutilh assisted InflaRx N.V. on a fully underwritten follow-on offering
NautaDutilh assisted InflaRx N.V. with its underwritten public offering of ordinary shares and warrants with a gross proceeds for InflaRx of USD 75 million. The shares are being sold at a public offering price of USD 5.00 per share. For each share purchased, an investor will also receive a warrant to purchase a common share at an exercise price of USD 5.80. The warrants are exercisable immediately and have a term of up to one year.
InflaRx is a Nasdaq listed clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx is a client of NautaDutilh since 2017.